<div id="readability-page-1"><div><p>BofAS issued a report stating that Akeso (09926.HK)<span> </span><span> +1.500 (+1.092%)  </span> <span> Short selling $224.69M; Ratio 23.189%  </span> 's cadonilimab recorded MoM growth against seasonality. In February, Akeso's sample drug sales amounted to RMB71.3 million, representing a YoY increase of 319.6%. Among which, cadonilimab sales reached RMB44.3 million, up 249.5% YoY and 9.6% MoM, achieving positive sequential growth during the Lunar New Year holiday period. Monthly sales of ivonescimab reached RMB26.6 million, continuing its volume expansion, with a YoY increase of 517.4%.The Buy rating on Akeso is maintained, with a TP of HKD162.8. (ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-27 16:25.)</p></div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p></div>

09926

520690

516930

<p>BofAS reported that Akeso's cadonilimab achieved month-over-month growth despite seasonal trends. In February, Akeso's drug sales reached RMB71.3 million, a 319.6% year-over-year increase, with cadonilimab sales at RMB44.3 million, up 249.5% YoY and 9.6% MoM. Ivonescimab also saw significant growth, with sales of RMB26.6 million, a 517.4% YoY increase. BofAS maintains a Buy rating on Akeso with a target price of HKD162.8.</p>

AASTOCKS News

AKESO

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

BofAS: Akeso  Cadonilimab Records MoM Growth Against Seasonality